Morin

Morin is a pentahydroxyflavonol that exerts antioxidant activity by scavenging DPPH radicals and superoxide anions, downregulates pro-inflammatory MAPK signaling (p-ERK and p-p38), and demonstrates selective antiproliferative effects against colorectal and hepatic cancer cell lines. At 100 ppm in vitro, morin reduced HepG2 hepatocellular carcinoma viability to 63.8%, HT-29 colorectal cell viability to 64.5%, and HCT-116 colorectal cell viability to 45.3%, while inhibiting xenograft tumor growth in animal models.

Origin & History

Morin is a naturally occurring flavonol polyphenol found primarily in plants of the Moraceae family, including white mulberry (Morus alba), as well as almond (Prunus dulcis), sweet chestnut (Castanea sativa), and the Arabian medicinal shrub Acridocarpus orientalis. It is distributed across subtropical and temperate regions spanning the Middle East, Asia, and the Mediterranean basin, where its host plants have been cultivated for centuries for food, timber, and traditional medicine. Commercial morin is typically isolated from methanolic extracts of these plant sources and standardized to ≥95% purity by HPLC for research and supplement applications.

Historical & Cultural Context

Morin takes its name from the Moraceae plant family, and its host plants — particularly mulberry species — have been integral to traditional medicine in East Asia, the Middle East, and the Mediterranean for thousands of years, used to treat inflammatory conditions, fever, and metabolic disorders. In Arabian Peninsula ethnomedicine, Acridocarpus orientalis, one of the identified morin-containing species, has been employed by local communities as a medicinal herb, and phytochemical investigations of its aerial parts have formalized morin's presence in this traditional pharmacopoeia. Almond and chestnut trees, also morin-bearing, hold prominent roles in European and Middle Eastern food cultures and were historically described in Greco-Roman herbalism for their astringent and anti-inflammatory properties, effects now partially attributable to flavonol constituents including morin. The compound itself was first isolated and chemically characterized in the mid-20th century, and modern phytochemical analysis has since confirmed its presence across diverse botanical families beyond Moraceae.

Health Benefits

- **Antioxidant Defense**: Morin scavenges DPPH free radicals at 97.96% efficiency and superoxide anions at 43.76%, while inhibiting lipid peroxidation by 75.22%, protecting cells from oxidative damage through direct radical quenching and reduction of reactive oxygen species.
- **Anti-Inflammatory Activity**: Morin suppresses MAPK pathway signaling by downregulating phosphorylated ERK (p-ERK) and phosphorylated p38 (p-p38) at concentrations of 25–40 µM, and reduces IgE levels in allergic airway inflammation animal models, attenuating both innate and adaptive immune-driven inflammation.
- **Anticancer Potential**: Dose-dependent suppression of HT-29 and HCT-116 colorectal cancer cell proliferation has been demonstrated in vitro, and morin inhibits HCT-116 xenograft tumor growth in vivo, suggesting multitarget antiproliferative mechanisms including induction of apoptotic pathways.
- **Skin Cytoprotection**: Liposomal morin at 25–40 µM promotes HaCaT keratinocyte proliferation and reduces particulate matter (PM)-induced ROS generation by approximately 50% at 25 µM, protecting epidermal cells from environmental oxidative insults.
- **Antifungal Activity**: Morin inhibits the growth of pathogenic fungi including Aspergillus niger, yielding a growth inhibition zone of 17.21 mm² at 1000 ppm, suggesting utility as a natural antifungal agent in food preservation or topical applications.
- **Antidiabetic Mechanisms**: Morin has been studied in preclinical models for glucose metabolism modulation, with evidence pointing to inhibition of oxidative stress pathways and inflammatory mediators implicated in insulin resistance, consistent with its broader anti-inflammatory and antioxidant profile.
- **Respiratory and Immune Modulation**: In animal models of allergic asthma, morin reduces IgE concentrations, indicating modulation of Th2-skewed immune responses and potential utility in atopic and allergic airway conditions.

How It Works

Morin's antioxidant effects stem from its polyhydroxylated flavonol structure, which donates hydrogen atoms to neutralize DPPH radicals (97.96% scavenging), superoxide anions (43.76%), and lipid peroxy radicals (75.22% inhibition of lipid peroxidation), thereby reducing oxidative burden at the cellular level. Its anti-inflammatory action involves downregulation of the MAPK signaling cascade, specifically decreasing phosphorylation of ERK and p38 kinases at 25–40 µM, which curtails transcription of pro-inflammatory cytokines and mediators. Anticancer activity appears to involve disruption of cell cycle progression and induction of apoptosis in colorectal and hepatic cancer cell lines, with HCT-116 xenograft suppression in vivo suggesting bioavailable systemic effects beyond in vitro conditions. Morin also reduces IgE synthesis in allergic airway models, implicating modulation of B-cell class switching and Th2 cytokine signaling as additional immunomodulatory mechanisms.

Scientific Research

The current evidence base for morin is largely preclinical, comprising in vitro cell culture studies and rodent animal models, with no published human randomized controlled trials reporting sample sizes or effect sizes at this time. In vitro studies have quantified antiproliferative activity against HepG2, HT-29, and HCT-116 cell lines at defined concentrations (100 ppm), and antioxidant potency has been characterized through DPPH, superoxide, and lipid peroxidation assays with reproducible results. Animal studies have demonstrated xenograft tumor suppression and attenuation of allergic airway inflammation, providing mechanistic plausibility but limited translational confidence. The evidence is therefore classified as preliminary-to-preclinical, and rigorous pharmacokinetic, dose-escalation, and clinical efficacy studies in humans are needed before therapeutic recommendations can be made.

Clinical Summary

No human clinical trials investigating morin as an isolated compound have been identified in the current literature, meaning all efficacy data derive from in vitro and animal experimental models. Key in vitro outcomes include dose-dependent reductions in cancer cell viability (HCT-116 to 45.3% at 100 ppm) and 50% reduction of PM-induced ROS in keratinocytes at 25 µM, which establish biological activity thresholds but do not confirm clinical efficacy. Animal model data support anti-tumor and anti-allergic activities, but species-specific pharmacokinetics, bioavailability, and tolerability in humans remain uncharacterized. Confidence in clinical applicability is low at present, and morin should be regarded as an investigational compound pending well-designed Phase I and Phase II human trials.

Nutritional Profile

Morin is a pure flavonol compound (molecular formula C₁₅H₁₀O₇, MW 302.24 g/mol) and does not contribute macronutrients (proteins, fats, carbohydrates) or classical micronutrients (vitamins, minerals) in isolation. As a polyphenol phytochemical, its biological value lies entirely in its five hydroxyl groups positioned at C-3, C-5, C-7, C-2′, and C-4′, which confer radical-scavenging capacity, metal chelation ability, and enzyme-modulating interactions. Natural concentrations in plant tissues are not precisely quantified across available literature, though morin is reported as a major flavonoid constituent alongside myricetin, quercetin, and rutin in sources such as Ganoderma lucidum isolates with high total phenol content. Bioavailability of the aglycone form is influenced by gut microbiome metabolism, lipophilicity, and formulation; liposomal delivery has been shown in cell studies to enhance intracellular uptake compared to free compound administration.

Preparation & Dosage

- **Standardized Powder (≥95% HPLC purity)**: The most reliable commercial form for research and supplementation; no clinically validated human dose has been established, but in vitro non-cytotoxic activity has been observed in the 10–100 µM range (~2.5–25 µg/mL).
- **Liposomal Formulation**: Liposomal morin at 25–40 µM has been used in cell-based skin studies to promote keratinocyte proliferation and reduce oxidative stress; encapsulation may improve membrane permeability and intracellular delivery.
- **Methanolic Plant Extract**: Traditional and research-grade preparation involves methanolic extraction of aerial parts of source plants (e.g., Acridocarpus orientalis, Morus alba), followed by chromatographic isolation; not standardized for consumer supplementation.
- **Crude Botanical Preparations**: Mulberry leaf and almond hull teas or decoctions provide morin alongside other flavonoids; morin content in crude preparations is variable and not quantified for reliable supplemental dosing.
- **Dosage Note**: No established human supplemental dose exists; in vitro cytotoxicity studies suggest concentrations above 100 µM (~25 µg/mL) may reduce normal cell viability (70% at 200 µM in HaCaT cells), indicating a need for careful dose determination in future clinical work.

Synergy & Pairings

Morin is structurally and mechanistically related to quercetin and myricetin, and co-occurrence with these flavonols in plant-derived extracts (e.g., Ganoderma lucidum isolates) suggests additive or synergistic antioxidant activity through complementary radical-scavenging pathways targeting different ROS species. Liposomal co-encapsulation with other polyphenols such as rutin may enhance cellular uptake and intracellular antioxidant capacity, as membrane-active delivery systems overcome the limited aqueous solubility of flavonols. In the context of anti-inflammatory supplementation, combining morin with omega-3 fatty acids or curcumin — which target COX-2 and NF-κB pathways not directly addressed by morin's MAPK inhibition — may provide broader pathway coverage, though this theoretical stack has not been tested in controlled studies.

Safety & Interactions

Morin is non-cytotoxic to normal keratinocytes (HaCaT cells) at concentrations below 100 µM, maintaining 100% cell viability in the 10–100 µM range, but viability drops to approximately 70% at 200 µM and 26% at 100 µM in liposomal form, indicating a dose-dependent cytotoxic threshold that warrants careful human dose characterization. No specific drug-drug interactions have been formally identified in the published literature, though morin's flavonol structure suggests potential inhibition of cytochrome P450 enzymes (particularly CYP1A2 and CYP3A4) by analogy with structurally related quercetin and myricetin, which could theoretically alter metabolism of co-administered pharmaceuticals. No data on safety during pregnancy or lactation are available, and use in these populations should be avoided until adequate safety studies are conducted. Phytotoxic activity at 100–500 ppm (EC₅₀ 33.82–49.21% on lettuce germination) serves as a reminder that biological potency extends to plant systems, and high-dose supplementation requires further toxicological profiling in mammals before safety thresholds can be formally established.